​

Funding Round

Series A - Intellia Therapeutics

Series A - Intellia Therapeutics

Investment Firm

Overview

Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.

Announced Date

Nov 18, 2014

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

Novartis

Novartis

No designation

Atlas Venture

Atlas Venture

Atlas Venture is a early_stage_venture and late_stage_venture and post_ipo and seed and venture firm.

Participant Investors

3

Investor Name
Participant InvestorCaribou Biosciences
Participant InvestorAtlas Venture
Participant InvestorNovartis

Round Details and Background

Intellia Therapeutics raised $15000000 on 2014-11-18 in Series A

Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.

Company Funding History

7

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Nov 30, 2020
Post-IPO Equity - Intellia Therapeutics
-201.0M
Jun 05, 2020
Post-IPO Equity - Intellia Therapeutics
-115.0M
Sep 01, 2015
Series B - Intellia Therapeutics
8-70.0M
Nov 18, 2014
Series A - Intellia Therapeutics
3-15.0M

Recent Activity

There is no recent news or activity for this profile.